

## WHAT IS CLAIMED IS:

1. A peptide originating from mammalian IL1 $\beta$  or TNF $\alpha$  cytokines, homologous to one of the following peptides of human IL1 $\beta$  or TNF $\alpha$  cytokines:

80 ISRIAVSYQTKVNLLS 95 (SEQ ID NO:2)

140 DYLDFAESGQVY 150 (SEQ ID NO:5)

3 VKSLNCTLRDSQQKSL 18 (SEQ ID NO:7)

45 SFVQGEESNDKIP 57 (SEQ ID NO:8)

89 NYPKKKMEKRQVFVNKIEI 106 (SEQ ID NO:9)

121 YISTSQAENMPVFLG 135 (SEQ ID NO:4)

143 ITDFTMQFVSS 153 (SEQ ID NO:10)

2. A peptide according to claim 1, wherein the human TNF $\alpha$  cytokine peptide sequence is ISRIAVSYQTKVNLLS (SEQ ID NO:2)

3. A peptide according to claim 1, wherein the human TNF $\alpha$  cytokine peptide sequence is DYLDFAESGQVY (SEQ ID NO:5)

4. A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is VKSLNCTLRDSQQKSL (SEQ ID NO:7).

5. A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is SFVQGEESNDKIP (SEQ ID NO:8).

6. A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is NYPKKKMEKRQVFVNKIEI (SEQ ID NO:9).

7. A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine peptide sequence is YISTSQAENMPVFLG (SEQ ID NO:4).

8. A peptide according to claim 1, wherein the human IL1 $\beta$  cytokine sequence is ITDFTMQFVSS (SEQ ID NO:10).

10. A derivative of the peptide according to any of claims 1 to 9.

11. A peptide according to one of claims 1 to 10 characterized in that it consists of less than 30 amino acids.

12. A derivative of a peptide as defined in any one of claims 1 to 11 by deletion, substitution, addition, cyclization,

stereochemical modification (use of D series amino acids) or functionalization (such as acylation) of one or more amino acids of said peptide.

13. An immunogenic compound characterized in that it comprises a peptide or peptide derivative as defined in any one of claims 1 to 12, it being understood that it comprises no other epitopes of said cytokine and in that it is capable of generating in a subject antibodies recognizing the native cytokine.

14. A peptide or peptide derivative or immunogenic compound as defined in any one of claims 1 to 13 for use in a method for preventive or therapeutic treatment of the human body.

15. A peptide or peptide derivative or immunogenic compound as defined in any one of claims 1 to 13 for use in a method for preventive or therapeutic treatment of the animal body (veterinary).

16. Use of a peptide or peptide derivative or immunogenic compound as defined in any one of claims 1 to 15 for the preparation of a curative or preventive medicament intended for the treatment or prevention of diseases linked to the presence or excess of cytokines.

17. A pharmaceutical composition which contains at least one peptide or peptide derivative or immunogenic compound as defined in any one of claims 1 to 15 as active ingredient.

18. Monoclonal or oligoclonal antibody specific to a peptide defined in any one of claims 1 to 15.

19. Use of the antibodies as defined in claim 18 for the preventive or therapeutic treatment of the human or animal body.

20. A method for the treatment of a disease associated with the pathogenic overproduction of  $IL1\beta$  or  $TNF\alpha$ , comprising administering to a patient in need thereof an antibody as defined in claim 18 to treat the disease associated with the pathogenic overproduction of  $IL1\beta$  or  $TNF\alpha$ .

21. A method for the treatment or prevention of diseases associated with the pathogenic overproduction of IL1 $\beta$  or TNF $\alpha$ , comprising administering to a patient in need thereof a peptide or peptide derivative or immunogenic compound as defined in any one of claims 1 to 15 to treat or inhibit the disease associated with the pathogenic overproduction of IL1 $\beta$  or TNF $\alpha$ .